RE:New year All eyes are on the phase 1a data release and the last we heard from TH they would have something on that front for us in January although the exact timing remained a bit foggy from my perspective. So, anyone's expectations are likely muddled at the moment due to the policy of radio silence the company has adopted. We have the impression that a drug trial goes on in a methodical fashion and that is probably largely correct but for a phase 1a trial with few participants and from a company with not background in cancer research, it is not hard to see how it might be much more chaotic than we imagine. TH is not wanting to say much of anything until they have a better understanding of the trial's results (they do not want to say anything they later might have to alter due to newer info coming in) and they likely do not have that yet. So, we are likely somewhere near the end of the trial and TH is not going to say anything until they have their messaging all sorted out.
As for the stock, it is now a totally forgotten stock. The analysts supposedly covering it really are not doing so and the next meaningful report will likely come from Cantor whenever the ATM is activated. So, the stock is in noman's land, the company is not talking and therefore, nothing much is happening in terms of trading volume. That may all change quickly but none if us can no for sure when that will happen.
Since they set up meetings with large investors for late January, that may indicate they will have news to share by then. But it also may just be an attempt to talk nicely to such shareholders so they don't vote against the slate of directors this year like some did last year.
There is always a chance that the trial is going to take longer because patients are easily tolerating the higher dosage amounts and they are moving higher on that front. More likely, since we saw some indication of an adverse event some time ago at the 420 mg level, is that the MTD is close at hand and will be either the 420 mg level or the previous level. They may simply be finalizing all the detailssurrounding that. And with covid messing with staffing levels at hospitals and other key contributirs to the phase 1a, that could be delaying things as well.
Needless to say, TH's track record on shareholder relations is less than optimal and leaving investors totally in the dark without even very generalized info about the state of the trial is unfortunate.
TH's stock price will react to news of signs of efficacy in the phase 1a, particluarly if it involves more than one tumor type. Given the time that has passed since the phase 1a has been at higher dosage levels, it will be disappointing if there is no sign of efficacy in this phase of the trial.
Additionally, you could get the stock reacting to any partnership deals on cancer or NASH. I don't think there are likely to be any big surprises on the legacy drug sales front that would move the stock a significant amount. It is all about phase 1a data and maybe parnterships right now.
Bucknelly21 wrote: Now that tax loss selling is done, what are the expectations from here forward